Molecular architecture of the tumor microenvironment caused by BRCA1 and BRCA2 somatic mutations in human lung adenocarcinoma.
Summary
This study characterized the molecular architecture of the tumor microenvironment (TME) in lung adenocarcinoma (LUAD) with somatic BRCA1/2 mutations, using single-cell sequencing and multi-omics data. BRCA1/2 mutations are linked to increased genomic instability and poor prognosis, yet predict better clinical outcomes with immune checkpoint blockade (ICB) treatment. BRCA1 mutations correlate with an upregulated type I IFN/IFN-γ signature and CD8+ T cell activation, while BRCA2 mutations are associated with inflammatory responses and enhanced MHC-II antigen presentation, influencing CD4+ T cell differentiation. The study also identified tissue-resident memory T cell (Trm) subsets as predictors of ICB response and found that a cancer-promoting program activated by BRCA1 is vulnerable to histone deacetylase inhibitors.
Analysis
This research is crucial as it reveals distinct differences in the impact of BRCA1 and BRCA2 mutations on the tumor microenvironment and immune response in LUAD. Understanding these specific molecular and immune profiles could enable more precise patient stratification for immunotherapy and identify novel therapeutic targets, such as the vulnerability of BRCA1-mutated tumors to histone deacetylase inhibitors. This paves the way for more personalized and potentially more effective treatment strategies for patients with lung adenocarcinoma.